

## Repository Corticotropin Injection

### DEFINITION

Repository Corticotropin Injection is Corticotropin in a solution of partially hydrolyzed gelatin. Its potency is NLT 80.0% and NMT 125.0% of the potency stated on the label in USP Corticotropin Units. It may contain a suitable antimicrobial agent.

### IDENTIFICATION

- **A.** Meets the requirements of the Assay.

### ASSAY

#### Change to read:

#### PROCEDURE

**Standard solution:** Pipet 2.5 mL of gelatin TS into an opened container of USP Corticotropin RS, and mix to obtain a solution having a concentration of 2.0 USP Corticotropin Units/mL. Using gelatin TS as a diluent, prepare three diluted *Standard solutions* such that the respective concentrations of corticotropin constitute a geometric series such as 1:2:4 or 1:3:9 and such that the quantity of corticotropin in each 0.5 mL lies within the range of 10–300 milliunits.

**Sample solution:** In the same manner, using the same diluent, dilute the Injection to give three *Sample solutions* corresponding in concentration to those of the *Standard solutions*.

**The animals:** Select healthy rats, of the same but either sex, that have been raised on a diet fully adequate with respect to vitamin and mineral content. Anesthetize the rats (IRA 1-Jul-2016) and remove the hypophysis from each by application of gentle suction through a fine-tipped tube. Between 16 and 48 h after the operation, select those rats weighing 80–180 g, but restrict the selection so that no rat is more than 30% heavier than the lightest, and the number of rats is an exact multiple of 6. Separate the selected rats into 6 groups, equal in size, of NLT 6 rats each, and assign at random one of the three diluted *Standard solutions* or one of the three *Sample solutions* to each group.

**Analysis:** Inject all rats of each group subcutaneously with the assigned test doses. Three h after the injection, anesthetize the rats, and remove both adrenal glands from each rat, free them from adhering tissue, and promptly weigh each pair on a suitable balance to the nearest 0.2 mg. Place the weighed glands from each rat in suitable vessels each containing 8.0 mL of metaphosphoric acid solution (1 in 40), and pulverize the glands by grinding with a small quantity of washed sand. Cover each vessel, and proceed similarly until all glands have been extracted.

**Ascorbic acid determination:** Filter the metaphosphoric acid extracts, and pipet 4 mL of each filtrate into suitable vessels each containing 4.0 mL of indophenol-acetate TS. Mix by shaking, and read the absorbance at 520 nm, with a suitable spectrophotometer. From the observed absorbance and the standard curve prepared as directed below, calculate the amount of ascorbic acid in mg/100 g of adrenal gland tissue. Prepare a standard concentration–absorbance curve, using three ascorbic acid solutions containing, respectively, 6.0, 8.0, and 10.0 µg/mL of USP Ascorbic Acid RS in metaphosphoric acid solution (1 in 40). Pipet into each of three suitable vessels, preferably spectrophotometer cells, 4 mL of indophenol-acetate TS. Add 4.0 mL of one of the three standard ascorbic acid

solutions to one of the cells, mix, and promptly read the absorbance from the same instrument and under the same conditions as for the adrenal gland extracts. Repeat the process for the other two standard ascorbic acid solutions, plot the concentration–absorbance values, and draw the straight line best fitting the three plotted points.

**Calculation:** If there are no missing data; i.e., all groups of rats are the same size,  $f$ , then the following may be used. [NOTE—If there are missing values, then suitable software can be used and standard procedures followed for parallel line bioassays, including assessment of parallelism and linearity.] Tabulate the observed concentration of ascorbic acid in the adrenal glands of each rat, designated by the symbol  $y_{jkl}$ , where  $j = S$  (Standard) or  $U$  (Injection),  $k = 1, 2, \text{ or } 3$  for the three doses, and  $l = 1, \dots, f$  rats. Total the values of the  $y_{jkl}$ 's in each group as:

$$T_{jk} = \sum_{l=1}^f y_{jkl}$$

Then determine the following quantities:

$$T_o = \sum_{k=1}^3 (T_{Uk} - T_{Sk})$$

$$T_b = (T_{U3} - T_{U1}) + (T_{S3} - T_{S1})$$

$$V = \frac{(T_{U3} - T_{U1})}{(T_{S3} - T_{S1})}$$

$$T_q = (T_{U3} - 2T_{U2} + T_{U1}) + (T_{S3} - 2T_{S2} + T_{S1})$$

$$T_{oq} = (T_{U3} - 2T_{U2} + T_{U1}) - (T_{S3} - 2T_{S2} + T_{S1})$$

$$s^2 = \frac{1}{n} \left[ \sum_{j,k,l} y_{jkl}^2 - \frac{1}{f} \sum_{j,k} T_{jk}^2 \right] \text{ where } n = 6(f-1)$$

$$\text{or } = \frac{1}{6} S_{jk}^2 \text{ where } S_{jk}^2 = \frac{1}{f-1} \sum_{l=1}^f (y_{jkl} - \frac{T_{jk}}{f})^2$$

$$F = \frac{T_o^2 + T_{oq}^2}{24fs^2}$$

If  $V \geq 0.75$  and  $V \leq 1.33$ , then the data satisfy parallelism. If  $F \leq F_{0.05,2,n}$ , where  $F_{0.05,2,n}$  is the upper 0.05 percentage point of an  $F$  distribution with 2 and  $n$  degrees of freedom, then the data satisfy linearity. If both conditions are satisfied, determine the logarithm of potency of the Injection,  $M$ , taken as:

$$M = M' + \log R,$$

$$\text{where } M' = 4iT_a/(3T_b)$$

$i$  = interval between successive log doses of both the *Standard solution* and the *Sample solution*  
 $R$  =  $v_s/v_u$ , the ratio of the high dose of the *Standard solution* in USP Corticotropin Units ( $v_s$ ) to the high dose of the Injection in mL ( $v_u$ )

Determine the width,  $L$ , of the log confidence interval as:

$$L = 2\sqrt{(C-1)(C(M')^2 + \frac{2}{3}i^2)}$$

$$\text{where } C = \frac{T_b^2}{(T_o^2 - 4fs^2t_{0.025,n}^2)}$$

## 2 Corticotropin

and  $t_{0.025,n}$  is the upper one-sided 0.025 percentage point (or two-sided 0.05 percentage point) of a  $t$ -distribution with  $n$  degrees of freedom.

**Replication:** Repeat the entire determination at least once. Test the agreement among the two or more independent determinations, and compute the weight for each (see *Design and Analysis of Biological Assays* <111>, *Combination of Independent Assays*). Calculate the weighted mean log-potency  $\bar{M}$  and its confidence interval,  $L_c$  (see <111>, *The Confidence Interval and Limits of Potency*). (ERR\_1\_Dec-2015) The potency,  $P$ , is satisfactory if  $P = \text{antilog } \bar{M}$  is 80%–125% of the labeled potency and if the confidence interval does not exceed 0.40.

**Acceptance criteria:** 80.0%–125.0%

### IMPURITIES

#### • VASOPRESSIN ACTIVITY

**Solution A:** Dissolve 6.6 g of dibasic ammonium phosphate in about 950 mL of water, and adjust with concentrated phosphoric acid to a pH of 3.0. Dilute with water to 1 L.

**Mobile phase:** Acetonitrile and *Solution A* (13:87). Filter and degas.

[NOTE—The retention time of the vasopressin peak is very sensitive to small changes in the acetonitrile concentration.]

**Standard solution:** Dissolve the entire contents of a vial of USP Vasopressin RS in a known volume of *Solution A*, and dilute with *Solution A* to obtain a final solution containing 0.1 USP Vasopressin Units/mL.

**Sample solution:** Dissolve the entire contents of a vial of Injection in a known volume of *Solution A*, and dilute with *Solution A* to obtain a final solution containing 2.0 USP Corticotropin Units/mL.

#### Chromatographic system

(See *Chromatography* <621>, *System Suitability*.)

**Mode:** LC

**Detector:** UV 220 nm

**Column:** 4.6-mm × 25-cm; 5- $\mu$ m packing L1

**Flow rate:** About 1.5 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the vasopressin activity in USP Vasopressin Units/USP Corticotropin Unit:

$$\text{Result} = C_s \times [(r_u/r_s)/2]$$

$C_s$  = concentration of the *Standard solution* (USP Vasopressin Units/mL)

$r_u$  = peak response from the *Sample solution*

$r_s$  = peak response from the *Standard solution*

**Acceptance criteria:** NMT 0.05 USP Vasopressin Units/USP Corticotropin Unit

### SPECIFIC TESTS

• **PH** <791>: 3.0–7.0

• **BACTERIAL ENDOTOXINS TEST** (85): NMT 3.1 USP Endotoxin Units/USP Corticotropin Unit

### Change to read:

• **INJECTIONS AND IMPLANTED DRUG PRODUCTS** <1>: (CN 1-MAY-2016) Meets the requirements

### ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in single-dose or multiple-dose containers, preferably of Type I glass.

• **USP REFERENCE STANDARDS** <11>

USP Ascorbic Acid RS

USP Corticotropin RS

USP Endotoxin RS

USP Vasopressin RS